A congressional hearing was called on Thursday to look into Vioxx, the arthritis drug with evidence that it may trigger heart and stroke problems. The question on Capital Hill: What took so long to pull it from the market when scientists were counting more than 100,000 reports of heart attacks or stokes linked to Vioxx, with the possibility of nearly 28,000 deaths.
"Only the positive studies, only the studies that show what the company wants get published. All the other studies get buried," says David Graham, FDA Scientist.
The FDA says it is concerned that Americans are influenced by skilled promotions and ask for the prescriptions they see advertised, whether they really need them or not.